• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BioLineRx Reports 2024 Financial Results and Provides Corporate Update

    3/31/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLRX alert in real time by email

    - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases -

    - Executed license agreement with Ayrmid Pharma Ltd. for APHEXDA® (motixafortide) with $10 million upfront payment, up to $87 million in commercial milestones, and high double-digit royalties on net sales -

    - Completed financings raising combined gross proceeds of $19 million and reduced operating expense run rate by 70%, extending the Company's cash runway through H2 2026 -

    - Management to host conference call today, March 31st, at 8:30 am EDT -

    TEL AVIV, Israel, March 31, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2024, and provided a corporate update.

    BioLineRx Ltd. Logo

    "It has been just over four months since we implemented a major strategy shift, highlighted by the transformational exclusive licensing agreement that we entered into with Ayrmid Ltd., granting it the rights to commercialize APHEXDA® (motixafortide) in all non-solid-tumor indications and all territories other than Asia," said Philip Serlin, Chief Executive Officer of BioLineRx. "Since then, we implemented cost efficiencies across the Company, including the shutdown of our U.S. commercial operations, that have resulted in an approximate 70% reduction in our operating expense base, which, together with recent financings, have put us on a firm footing with a cash runway through the second half of 2026."

    "As we return to our roots as a lean drug development company, with a highly validated development platform focused on oncology and rare diseases, we believe these actions help ensure that we remain nimble and capable of seizing the opportunities in front of us. Our strategy moving forward is to in-license additional assets over the next year that we can advance through clinical proof-of-concept, funded in part by milestones and royalties from our out-licensing transactions. To that end, I am pleased to report that we are evaluating numerous promising candidates. This process is methodical and steady to ensure that our due diligence is thorough as we look for new chemical entities. Based on our deep and validated experience in drug development, I believe we are well positioned to create sustained value for our shareholders. I am excited about what the future holds for our Company this year and beyond," Mr. Serlin concluded.

    Corporate Updates

    • Executed license agreement with Ayrmid Pharma Ltd. to develop and commercialize APHEXDA® (motixafortide) in all indications except solid tumors, and across all territories except Asia

      - License agreement included a $10 million upfront payment, up to $87 million in potential commercial milestones, and royalties on net sales ranging from 18% to 23%
    • Announced receipt of a Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) for a patent, titled "Composition of BL-8040," which strengthens BioLineRx's robust intellectual property (IP) estate and extends its patent protection on motixafortide (BL-8040) in the U.S. through December 2041

    Financial Updates

    • Completed two financings in past few months which raised combined gross proceeds of $19 million
    • Reduced operating expense run rate by approximately 70% beginning January 1, 2025 through the APHEXDA program transfer to Ayrmid and the resulting shutdown of the Company's U.S. commercial operations in Q424, as well as additional headcount and other operating expense reductions
    • Significantly reduced outstanding debt and restructured the remainder on favorable terms to the Company

    APHEXDA 2024 Performance Update

    • Aphexda achieved 10 percent market share of total CXCR4 inhibitor usage in the U.S., which compares APHEXDA to branded MOZOBIL and generic plerixafor in all indications
    • BioLineRx generated more than $6 million in net product sales year-to-date through the November 2024 completion of the Ayrmid out-licensing transaction

    Clinical Updates

    Motixafortide

    Pancreatic Ductal Adenocarcinoma (mPDAC)

    • Additional trial sites activated for the CheMo4METPANC Phase 2b clinical trial being led by Columbia University. Full enrollment in the randomized trial targeting 108 patients is anticipated in 2027, with a prespecified interim futility analysis planned when 40% of PFS events are observed   

    Sickle Cell Disease (SCD) & Gene Therapy

    • First patient dosed in the multi-center Phase 1 clinical trial evaluating motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with Sickle Cell Disease (SCD). The trial is sponsored by St. Jude Children's Research Hospital.
    • Oral presentation delivered at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition detailing initial results from a Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in SCD. Sponsored by investigators at Washington University in St. Louis, the findings from this proof-of-concept study suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle.

    Financial Results for the Year Ended December 31, 2024

    • Revenues for the year ended December 31, 2024 were $28.9 million, an increase of $24.1 million, or 502.1%, compared to $4.8 million for the year ended December 31, 2023. The revenues in 2024 primarily reflect a portion of the up-front payment received, and a milestone payment achieved, under the Gloria license, which collectively amounted to $15.0 million, as well as the up-front payment received under the Ayrmid license and $6.0 million of net revenues from product sales of APHEXDA in the U.S. The revenues in 2023 (all of which were recorded in the fourth quarter of 2023) primarily reflect a portion of the up-front payment received under the Gloria license of $4.6 million, as well as $0.2 million of revenues from product sales of APHEXDA in the U.S.
    • Cost of revenues for the year ended December 31, 2024 were $9.3 million, an increase of $5.6, or 151.4%, compared to $3.7 million for the year ended December 31, 2023. The cost of revenues in 2024 primarily reflects amortization of intangible assets, Biokine's share of the up-front payment received under the Ayrmid license, sub-license fees accrued on a milestone payment recorded under the Gloria license, as well as royalties on net product sales of APHEXDA in the U.S. and cost of goods sold on product sales. The cost of revenues in 2023 primarily reflects Biokine's share of the up-front payment received under the Gloria license and of the net sales.
    • Research and development expenses for the year ended December 31, 2024 were $9.2 million, a decrease of $3.3 million, or 26.4%, compared to $12.5 million for the year ended December 31, 2023. The decrease resulted primarily from lower expenses related to motixafortide NDA supporting activities, termination of the development of AGI-134 and a decrease in payroll and share-based compensation.
    • Sales and marketing expenses for the year ended December 31, 2024 were $23.6 million, a decrease of $1.7 million, or 6.7%, compared to $25.3 million for the year ended December 31, 2023. The decrease resulted primarily from the shutdown of U.S. commercial operations in the fourth quarter of 2024 following the Ayrmid license.
    • General and administrative expenses for the year ended December 31, 2024 were $6.3 million, similar to the year ended December 31, 2023.
    • Net non-operating income amounted to $18.4 million for the year ended December 31, 2024, compared to net non-operating expenses of $10.8 million for the year ended December 31, 2023. Non-operating income for the year ended December 31, 2024 primarily relates to non-cash, fair-value adjustments of warrant liabilities on the Company's balance sheet, as a result of changes in the Company's share price, offset by warrant offering expenses. Non-operating expenses for the year ended December 31, 2023 primarily relate to non-cash, fair-value adjustments of warrant liabilities on the Company's balance sheet. 
    • Net financial expenses amounted to $7.3 million for the year ended December 31, 2024, compared to net financial expenses of $0.1 million for the year ended December 31, 2023. Net financial expenses for both periods primarily relate to interest paid on loans, which increased in 2024 due to a one-time $4.0 million charge to interest expense in connection with the November 2024 amendment to the loan agreement with BlackRock, partially offset by investment income earned on bank deposits.
    • Net loss for the year ended December 31, 2024 was $9.2 million, compared to $60.6 million for the year ended December 31, 2023.
    • As of December 31, 2024, the Company had cash, cash equivalents, and short-term bank deposits of $19.6 million (approximately $29.0 million on a pro-forma basis, following the financing completed at the beginning of January 2025).

    A copy of the Company's annual report on Form 20-F for the year ended December 31, 2024 has been filed with the U.S. Securities and Exchange Commission at https://www.sec.gov/ and posted on the Company's investor relations website at https://ir.biolinerx.com.The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request at [email protected].

    Conference Call and Webcast Information

    To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until April 2, 2025; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

    About BioLineRx

    BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding Asia) and Gloria Biosciences (in Asia). BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside.

    Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  

    Forward Looking Statement

    Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the potential success of the license agreement with Ayrmid and the commercial potential of motixafortide, expectations with regard to clinical trials of motixafortide, the expected cash runway, and BioLineRx's business strategy. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates, including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials, and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials, whether the clinical trial results for APHEXDA will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; and statements as to the impact of the political and security situation in Israel on BioLineRx's business, which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2025. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

    Contacts:

    United States

    Irina Koffler

    LifeSci Advisors, LLC

    [email protected]

    Israel

    Moran Meir

    LifeSci Advisors, LLC

    [email protected]

     

     

    BioLineRx Ltd.

    CONSOLIDATED STATEMENTS OF FINANCIAL POSITION







    December 31,





    2023

    2024





    in USD thousands

    Assets







    CURRENT ASSETS







    Cash and cash equivalents



    4,255

    10,436

    Short-term bank deposits



    38,739

    9,126

    Trade receivables



    358

    2,476

    Prepaid expenses



    1,048

    443

    Other receivables



    830

    1,478

    Inventory



    1,953

    3,145

          Total current assets



    47,183

    27,104









    NON-CURRENT ASSETS







    Property and equipment, net



    473

    386

    Right-of-use assets, net



    1,415

    967

    Intangible assets, net



    14,854

    10,449

              Total non-current assets



    16,742

    11,802

              Total assets



    63,925

    38,906









    Liabilities and equity







    CURRENT LIABILITIES







    Current maturities of long-term loan



    3,145

    4,479

    Contract liabilities



    12,957

    -

    Accounts payable and accruals:







         Trade



    10,869

    5,583

         Other



    3,353

    3,131

    Current maturities of lease liabilities



    528

    522

    Warrants



    11,932

    1,691

              Total current liabilities



    42,784

    15,406









    NON-CURRENT LIABILITIES







    Long-term loan, net of current maturities



    6,628

    8,958

    Lease liabilities



    1,290

    1,081

              Total non-current liabilities



    7,918

    10,039









     

    COMMITMENTS AND CONTINGENT LIABILITIES







              Total liabilities



    50,702

    25,445









    EQUITY







    Ordinary shares



    31,355

    38,097

    Share premium



    355,482

    353,693

    Warrants



    1,408

    5,367

    Capital reserve



    17,000

    17,547

    Other comprehensive loss



    (1,416)

    (1,416)

    Accumulated deficit



    (390,606)

    (399,827)

              Total equity



    13,223

    13,461

              Total liabilities and equity



    63,925

    38,906

     

     

    BioLineRx Ltd.

    CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS







    Year ended December 31,





    2022

    2023

    2024





    in USD thousands











    REVENUES:









     License revenues

    -

    4,610

    22,917

         Product sales, net



    -

    190

    6,023

              Total revenues



    -

    4,800

    28,940

    COST OF REVENUES



    -

    (3,692)

    (9,263)

    GROSS PROFIT



    -

    1,108

    19,677

    RESEARCH AND DEVELOPMENT EXPENSES



    (17,629)

    (12,519)

    (9,149)

    SALES AND MARKETING EXPENSES



    (6,462)

    (25,270)

    (23,605)

    GENERAL AND ADMINISTRATIVE EXPENSES



    (5,066)

    (6,310)

    (6,321)

    IMPAIRMENT OF INTANGIBLE ASSETS



    -

    (6,703)

    (1,010)

    OPERATING LOSS



    (29,157)

    (49,694)

    (20,408)

    NON-OPERATING INCOME (EXPENSES), NET



    5,670

    (10,819)

    18,435

    FINANCIAL INCOME



    694

    2,068

    1,871

    FINANCIAL EXPENSES



    (2,158)

    (2,169)

    (9,119)

    LOSS AND COMPREHENSIVE LOSS



    (24,951)

    (60,614)

    (9,221)















    in USD

    LOSS PER ORDINARY SHARE – BASIC AND DILUTED



    (0.03)

    (0.06)

    (0.01)











    WEIGHTED AVERAGE NUMBER OF SHARES USED IN

    CALCULATION OF LOSS PER ORDINARY SHARE



    773,956,973

    963,365,525

    1,198,107,761























     

     

    BioLineRx Ltd.

    STATEMENTS OF CHANGES IN EQUITY





     

    Ordinary

    shares

     

    Share

    premium

     

     

    Warrants

     

    Capital

    reserve

    Other

    comprehensive 

    loss

     

    Accumulated

    deficit

     

     

    Total



    in USD thousands

    BALANCE AT JANUARY 1, 2022

    21,066

    339,346

    975

    13,157

    (1,416)

    (305,041)

    68,087

    CHANGES IN 2022:















      Issuance of share capital and warrants, net

    6,029

    (1,007)

    433

    -

    -

    -

    5,455

      Employee stock options exercised

    5

    14

    -

    (14)

    -

    -

    5

      Employee stock options expired

    -

    623

    -

    (623)

    -

    -

    -

      Share-based compensation   

    -

    -

    -

    2,245

    -

    -

    2,245

      Comprehensive loss for the year

    -

    -

    -



    -

    (24,951)

    (24,951)

    BALANCE AT DECEMBER 31, 2022

    27,100

    338,976

    1,408

    14,765

    (1,416)

    (329,992)

    50,841

    CHANGES IN 2023:















      Issuance of share capital, net

    3,242

    10,847

    -

    -

    -

    -

    14,089

      Warrants exercised

    1,000

    5,559

    -

    -

    -

    -

    6,559

      Employee stock options exercised

    13

    45

    -

    (31)

    -

    -

    27

      Employee stock options expired

    -

    55

    -

    (55)

    -

    -

    -

      Share-based compensation   

    -

    -

    -

    2,321

    -

    -

    2,321

      Comprehensive loss for the year

    -

    -

    -

    -

    -

    (60,614)

    (60,614)

    BALANCE AT DECEMBER 31, 2023

    31,355

    355,482

    1,408

    17,000

    (1,416)

    (390,606)

    13,223

    CHANGES IN 2024:















      Issuance of share capital and warrants, net

    4,712

    (3,060)

    6,650

    -

    -

    -

    8,302

    Pre-funded warrants exercised

    2,009

    682

    (2,691)

    -

    -

    -

    -

      Employee stock options exercised

    21

    50

    -

    (49)

    -

    -

    22

      Employee stock options expired

    -

    539

    -

    (539)

    -

    -

    -

      Share-based compensation   

    -

    -

    -

    1,135

    -

    -

    1,135

      Comprehensive loss for the year

    -

    -

    -

    -

    -

    (9,221)

    (9,221)

    BALANCE AT DECEMBER 31, 2024

    38,097

    353,693

    5,367

    17,547

    (1,416)

    (399,827)

    13,461

     

     

    BioLineRx Ltd.

    CONSOLIDATED STATEMENTS OF CASH FLOWS





    Year ended December 31,



    2022

    2023

    2024



    in USD thousands

    CASH FLOWS - OPERATING ACTIVITIES







         Loss

    (24,951)

    (60,614)

    (9,221)

         Adjustments required to reflect net cash used in operating

              activities (see appendix below)

    (1,289)

    38,006

    (34,652)

    Net cash used in operating activities

    (26,240)

    (22,608)

    (43,873)









    CASH FLOWS - INVESTING ACTIVITIES







         Investments in short-term deposits

    (44,000)

    (47,588)

    (26,350)

         Maturities of short-term deposits

    48,322

    49,329

    55,778

         Purchase of property and equipment

    (131)

    (116)

    (53)

         Purchase of intangible assets

    (185)

    (181)

    (1)

    Net cash provided by investing activities

    4,006

    1,444

    29,374









    CASH FLOWS - FINANCING ACTIVITIES







         Issuance of share capital and warrants, net of issuance costs

    14,359

    14,089

    16,357

         Exercise of warrants

    -

    2,928

    -

         Employee stock options exercised

    5

    27

    22

    Proceeds from long-term loan, net of issuance costs

    9,126

    -

    19,223

         Repayments of loan

    (2,832)

    (1,543)

    (14,433)

         Repayments of lease liabilities

    (220)

    (445)

    (511)

    Net cash provided by financing activities

    20,438

    15,056

    20,658









    INCREASE )DECREASE( IN CASH AND CASH

        EQUIVALENTS

    (1,796)

    (6,108)

    6,159

    CASH AND CASH EQUIVALENTS - BEGINNING

       OF YEAR

    12,990

    10,587

    4,255

    EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS

    (607)

    (224)

    22

    CASH AND CASH EQUIVALENTS - END OF YEAR

    10,587

    4,255

    10,436









     

    BioLineRx Ltd.





    CONSOLIDATED STATEMENTS OF CASH FLOWS 



















    Year ended December 31,







    2022

    2023

    2024







    in USD thousands





    APPENDIX























    Adjustments required to reflect net cash used in operating activities: 











    Income and expenses not involving cash flows: 











    Depreciation and amortization

    654

    1,384

    4,065





    Exchange differences on cash and cash equivalents

    607

    224

    (22)





    Fair value adjustments of warrants

    (6,425)

    11,054

    (18,965)





    Share-based compensation

    2,245

    2,321

    1,135





    Interest and exchange differences on short-term deposits

    (672)

    15

    185





    Interest on loan

    1,117

    1,148

    (1,126)





    Warrant issuance costs

    171

    -

    669





    Exchange differences on lease liabilities

    (224)

    (42)

    (31)





    Intangible assets impairment

    -

    6,703

    1,010





    Loss on abandonment of right-of-use asset

    -

    -

    246







    (2,527)

    22,807

    (12,834)

















    Changes in operating asset and liability items:











    Increase in trade receivables 

    -

    (358)

    (2,118)





    Increase in inventory

    -

    (1,953)

    (1,192)





    Increase in prepaid expenses and other receivables

    (650)

    (959)

    (43)





    Increase (decrease) in accounts payable and accruals

    1,888

    5,512

    (5,508)





    Increase (decrease) in contract liabilities 

    -

    12,957

    (12,957)







    1,238

    15,199

    (21,818)







    (1,289)

    38,006

    (34,652)





























    Supplemental information on interest received in cash

    342

    2,020

    1,992





    Supplemental information on interest paid in cash

    593

    1,111

    10,387

















    Supplemental information on non-cash transactions:







    Changes in right-of-use asset and lease liabilities

    706

    149

    327





    Warrant issuance costs

    262

    -

    -





    Purchase of property and equipment

    28

    -

    -





    Fair value of exercised warrants (portion related to accumulated

     fair value adjustments)

    -

    3,631

    -





     

    Logo - https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/biolinerx-reports-2024-financial-results-and-provides-corporate-update-302415505.html

    SOURCE BioLineRx Ltd.

    Get the next $BLRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BLRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for APHEXDA issued to BIOLINERX, LTD.

      Submission status for BIOLINERX, LTD.'s drug APHEXDA (ORIG-1) with active ingredient MOTIXAFORTIDE has changed to 'Approval' on 09/08/2023. Application Category: NDA, Application Number: 217159, Application Classification: Type 1 - New Molecular Entity

      9/11/23 2:15:50 PM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by BioLineRx Ltd. (Amendment)

      SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

      2/11/22 6:49:45 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

      2/16/21 4:10:22 PM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

      2/12/21 9:40:57 PM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioLineRx Reports 2024 Financial Results and Provides Corporate Update

      - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. for APHEXDA® (motixafortide) with $10 million upfront payment, up to $87 million in commercial milestones, and high double-digit royalties on net sales - - Completed financings raising combined gross proceeds of $19 million and reduced operating expense run rate by 70%, extending the Company's cash runway through H2 2026 - - Management to host conference call today, March 31st, at 8:30 am EDT - TEL AVIV, Israel, March 31, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a developme

      3/31/25 7:00:00 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioLineRx to Report 2024 Annual Results on March 31, 2025

      Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, March 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open.   The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed th

      3/24/25 7:00:00 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cognyte Elects Two New Board Members to Strengthen Expertise and Drive Growth

      Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f

      2/18/25 8:00:00 AM ET
      $ALLT
      $BLRX
      $CGEN
      $CGNT
      Computer Communications Equipment
      Telecommunications
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLRX
    SEC Filings

    See more
    • SEC Form 6-K filed by BioLineRx Ltd.

      6-K - BioLineRx Ltd. (0001498403) (Filer)

      3/31/25 7:04:10 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by BioLineRx Ltd.

      20-F - BioLineRx Ltd. (0001498403) (Filer)

      3/31/25 7:01:06 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BioLineRx Ltd.

      6-K - BioLineRx Ltd. (0001498403) (Filer)

      1/21/25 7:11:35 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright reiterated coverage on BioLineRx with a new price target

      HC Wainwright reiterated coverage of BioLineRx with a rating of Buy and set a new price target of $19.00 from $22.00 previously

      3/1/21 8:36:34 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright resumed coverage on BioLineRx

      HC Wainwright resumed coverage of BioLineRx with a rating of Buy

      2/23/21 11:53:43 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on BioLine Rx with a new price target

      HC Wainwright & Co. reiterated coverage of BioLine Rx with a rating of Buy and set a new price target of $19.00 from $22.00 previously

      2/23/21 11:24:05 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLRX
    Financials

    Live finance-specific insights

    See more

    $BLRX
    Leadership Updates

    Live Leadership Updates

    See more
    • BioLineRx Reports 2024 Financial Results and Provides Corporate Update

      - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. for APHEXDA® (motixafortide) with $10 million upfront payment, up to $87 million in commercial milestones, and high double-digit royalties on net sales - - Completed financings raising combined gross proceeds of $19 million and reduced operating expense run rate by 70%, extending the Company's cash runway through H2 2026 - - Management to host conference call today, March 31st, at 8:30 am EDT - TEL AVIV, Israel, March 31, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a developme

      3/31/25 7:00:00 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioLineRx to Report 2024 Annual Results on March 31, 2025

      Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, March 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open.   The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed th

      3/24/25 7:00:00 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

      - Executed license agreement with Ayrmid Ltd. for APHEXDA® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales - - Received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC - - Entered into agreement to reduce and restructure long-term debt by ~$16.5 million - - Annual operational expenses expected to decline by over 70% following out-license of APHEXDA® (motixafortide) commercial program to Ayrmid - - Company to continue to support motixafortide PDAC program while evaluating additional assets for development in rare diseases and oncology - - Management to host conference call t

      11/25/24 7:00:00 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cognyte Elects Two New Board Members to Strengthen Expertise and Drive Growth

      Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f

      2/18/25 8:00:00 AM ET
      $ALLT
      $BLRX
      $CGEN
      $CGNT
      Computer Communications Equipment
      Telecommunications
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

      Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing nov

      12/10/24 8:30:00 AM ET
      $BLRX
      $SLXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

      Experienced Drug Developer Brings Over 15 Years of Clinical Development Industry Knowledge across Multiple Therapeutic Areas and Modalities TEL AVIV, Israel, Jan. 4, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer.  Dr. Rachmilewitz will report to the CEO and lead the Company's clinical and medical functions.  Her appointment is effective today, January 4, 2023. "Tami has tremendous experience across a range of therapeutic areas and drug development modalities," said Philip Serlin, Chief Executive Officer of BioLineRx. 

      1/4/23 7:00:00 AM ET
      $BLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care